Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120548 | 0.86 | HDAC1 (0.76) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL4282116 | 0.83 | HDAC1 (0.54) | HDAC1P2RY14HDAC2HDAC3KCNH2 | |
| SCHEMBL4003291 | 0.81 | HDAC1 (0.50) | HDAC1P2RY14HDAC2KCNH2MAPT | |
| SCHEMBL651437 | 0.80 | HDAC1 (0.67) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL4312605 | 0.80 | HDAC1 (0.53) | HDAC1P2RY14HDAC2HDAC3KCNH2 | |
| SCHEMBL3643629 | 0.79 | HDAC1 (0.77) | HDAC1P2RY14HDAC2HDAC3KCNH2 | |
| SCHEMBL975555 | 0.79 | KCNH2 (0.56) | HDAC1P2RY14KCNH2MAPTCHEK2 | |
| SCHEMBL14975340 | 0.78 | HDAC1 (0.79) | HDAC1HDAC2HDAC3 | |
| SCHEMBL651516 | 0.78 | HDAC1 (0.53) | HDAC1P2RY14HDAC2HDAC3KCNH2 | |
| SCHEMBL4578938 | 0.78 | HDAC1 (0.74) | HDAC1HDAC2HDAC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221669-A1 | Disubstituted Aniline Compounds | TXNRD2, BRDT, HDAC1 | HDAC1 3/4885P2RY14 4850/4885HDAC2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.